ID
24662
Description
Study part: The Structured Interview For The Diagnosis Of RLS (SIDA_A). A 52-Week, Open-Label Study to Assess the Long-Term Safety of Ropinirole Extended Release (XR) in Patients with Restless Legs Syndrome (RLS). Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Clinicaltrials.gov Identifier: NCT00355641. Phase: phase 3. Study Recruitment Status: Completed. Generic Name: ropinirole. Trade Name Modutab, ZIPEREVE, ZEPREVE, REPREVE, ADARTREL, REQUIP, Zygara; Zygara, ZIPEREVE, ZEPREVE, Requip Depot, REQUIP, REPREVE, Modutab, ADARTREL. Study Indication : Restless Legs Syndrome. Study ID: 101468/206. Clinical Study ID: 101468/206.
Keywords
Versions (1)
- 8/12/17 8/12/17 -
Copyright Holder
GlaxoSmithKline
Uploaded on
August 12, 2017
DOI
To request one please log in.
License
Creative Commons BY-NC 3.0
Model comments :
You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.
Itemgroup comments for :
Item comments for :
In order to download data models you must be logged in. Please log in or register for free.
The Structured Interview For The Diagnosis Of RLS (SIDA_A) Ropinirole Restless Legs Syndrom NCT00355641
The Structured Interview For The Diagnosis Of RLS (SIDA_A)
- StudyEvent: ODM
Similar models
The Structured Interview For The Diagnosis Of RLS (SIDA_A)
- StudyEvent: ODM
C0035258 (UMLS CUI-2)
C0035258 (UMLS CUI [1,2])